General Framework
Structure
Main National and International Collaborations and Reference Groups
Areas of Research
Main ongoing Research Activities and Projects
Methodologies and Facilities
Selected References
Cardio.Care
Internet links in cardiology
7. REFERENCES






La Rovere MT, Staszewsky L, Barlera S, Maestri R, Mezzani A, Midi P, Marchioli R, Maggioni AP, Tognoni G, Tavazzi L, Latini R, GISSI-HF Investigators
n-3PUFA and holter derived autonomic variables in heart failure patients: Data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter Substudy
Heart Rhythm 2013. 10 : 226 - 232


Masson S, Marchioli R, Mozaffarian D, Bernasconi R, Milani V, Dragani L, Tacconi M, Marfisi RM, Borgese L, Cirrincione V, Febo O, Nicolis E, Maggioni AP, Tognoni G, Tavazzi L, Latini R, on behalf of the GISSI-HF Investigators
Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure trial: Relation with fish intake, circulating biomarkers and mortality
Am Heart J 2013. 165 : 208 - 215.e4


Levantesi G, Marfisi RM, Mozaffarian D, Franzosi MG, Maggioni AP, Nicolosi GL, Schweiger C, Silletta MG, Tavazzi L, Tognoni G, Marchioli R
Wine consumption and risk of cardiovascular events after myocardial infarction: Results from the GISSI-Prevenzione trial
Int J Cardiol 2013. 163 : 282 - 287


Ueland T, Nymo S H , Latini R, McMurray J J V, Kjekshus J, Yndestad A, Fucili A, Grosu A, Masson S, Maggioni A P, Gullestad L, Aukrust P, on behalf of the Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) , GISSI-Heart Failure (GISSI-HF) trials
CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials
Eur Heart J Fail 2013. 15 : 747 - 755


Disertori M, Franzosi MG, Barlera S, Cosmi F, Quintarelli S, Favero C, Cappellini G, Fabbri G, Maggioni AP, Staszewsky L, Moroni LA, Latini R, on behalf of the GISSI-AF investigators
Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial
BMC Cardiovasc Disord 2013. 13: : 28


La Rovere MT, Pinna GD, Maestri R, Barlera S, Bernardinangeli M, Veniani M, Nicolosi GL, Marchioli R, Tavazzi L, for the GISSI-HF Investigators
Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial
Eur Heart J Fail 2012. 14 : 1410 - 1419


Latini R, Gullestad L, Masson S, Nymo SH , Ueland T, Cuccovillo I, Vårdal M , Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L, Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trial
Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials
Eur J Heart Fail 2012. 14 : 992 - 999


Staszewsky L, Wong M, Masson S, Raimondi E, Gramenzi S, Proietti G, Bicego D, Emanuelli C, Pulitanò G, Taddei F, Nicolis EB, Correale E, Fabbri G, Bertocchi F, Franzosi MG, Maggioni AP, Tognoni G, Disertori M, Latini R; GISSI-AF Investigators
Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy.
Circ Cardiovascular Imaging 2011. 4(6) : 721 - 728


Gori F, Specchia C, Pietri S, Crociati L, Barlera S, Franciosi M, Nicolucci A, Signorini S, Brambilla P, Franzosi MG; GISSI Prevenzione Investigators; SIBioC-GISSI Prevenzione Group
Common genetic variants on chromosome 9p21 are associated with myocardial infarction and type 2 diabetes in an Italian population.
BMC Med Genet 2010. 11 : 60


GISSI-AF Investigators
Valsartan for prevention of recurrent atrial fibrillation.
New Engl J Med 2009. 360(16) : 1606 - 1617


Clarke R , Peden J F, Jemma C, Kyriakou T, Goel A, Heath S C, Parish S, Barlera S, Franzosi M G, Rust S, Bennett D, Silveira A, Malarstig A , Green F R, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M, PROCARDIS Consortium
Genetic variants associated with Lp(a) lipoprotein level and coronary disease
New Engl J Med 2009. 361(26) : 2518 - 2528


Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli S, Tognoni G, Tavazzi L; GISSI-HF Investigators.
Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial.
Eur Heart J 2009. 30(19) : 2327 - 2336


GISSI-HF Investigators
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
Lancet 2008. 372 : 1223 - 1230


GISSI-HF Investigators
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
Lancet 2008. 372 : 1231 - 1239


Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, Vago T, Maggioni AP, Anand IS, Tan LB, Tognoni G, Cohn JN, for the Val-HeFT Investigators
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.
Am J Med 2006. 119 : 70.e23 - 70.e30


Monesi L, Avanzini F, Roncaglioni MC
Response to Nauton and Dyyvendak re "Appropriate use of antiplatelets: is precription in daily practice influenced by the global cardiovasuclar risk?"
Eur J Clin Pharmacol 2006. 62 : 79 - 80


Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL
Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized controlled trials
JAMA 2006. 295 : 306 - 313


Grunewald M, Avraham I, Dor Y, Bachar-Lustin E, Itin A, Yung S, Chimenti S, Limor L, Abramovitch R, Keshet E
VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells
Cell 2006. 124 : 175 - 189


The OASIS-5 Randomized Trial: Franzosi MG, Gardinale E, Turazza F
Comparison of Fondaparinux and Enoxaparin in acute coronary syndromes
N Engl J Med 2006. 354 : 1646 - 1676


The OASIS-6 Randomized Trial
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment evevation myocardial infarction.
JAMA 2006. 295 : E1 - E12


Anand IS, Latini R, Florea VG, Kuskowski MS, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN, for the Val-HeFT Investigators.
C-reactive protein in heart failure: prognostic value and the effect of valsartan
Circulation 2005. 112 : 1428 - 1434


Corada M, Chimenti S, Cera MR, Vinci M, Salio M, Fiordaliso F, De Angelis N, Villa A, Bossi M, Staszewsky LI, Vecchi A, Parazzoli D, Motoike T, Latini R, Dejana E
Junctional adhesion molecule-A-deficient polymorphonuclear cells show reduced diapedesis in peritonitis and heart ischemia-reperfusion injury
Proc Natl Acad Sci USA 2005. 102 : 10634 - 10639


Cholesterol Treatment Trialists' (CTT) Collaborators
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins.
Lancet 2005. 366 : 1267 - 1278


Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai Jr P, Razak F, Sharma AM, Anand SS, on behalf of the INTERHEART Study Investigators.
Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study.
Lancet 2005. 366 : 1640 - 1649


MICHELANGELO OASIS 5 Steering Committee
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Am Heart J 2005. 150 : 1107e.1 - 1107e.10


Maggioni AP, Franzosi MG, Latini R.
Beta-adrenoceptor antagonists and antianginal drugs.
2005. 28 : 217 - 222


Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN.
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
Am Heart J 2005. 149 : 548 - 557


Franzosi MG, Garattini S
Thrombolytic therapy in acute myocardial infarction. 20 years of GISSI
J Thromb Haemost 2005. 3 : 2807 - 2808


Anand S, Xie CC, Metha S, Franzosi MG, Joyner C, Chrolavicius S, Fox KAA, Yusuf S. for the CURE investigators
Differences in the management and prognosis of women and men who suffer from acute coronary syndromes.
J Am Coll Cardiol 2005. 46 : 1845 - 1851


The PROCARDIS Consortium
A trio family study showing association of the lymphotoxin-alfa N26 (804 A) allele with coronary artery disease.
Eur J Human Genetics 2004. 12 : 770 - 774


Maggioni AP, Franzosi MG, Latini R.
Beta-adrenoceptor antagonists and antianginal drugs
In: 2003. 26 : 223 - 229


Chiodini BD, Barlera S, Franzosi MG, Labarta Beceiro V, Introna M, Tognoni G
APO B gene polymorphisms and coronary artery disease: a meta-analysis
Atherosclerosis 2003. 167 : 355 - 366


Latini R, Staszewsky L, Maggioni AP, Marino P, Hernández-Bernal F, Tognoni G, Labarta V, Gramenzi S, Bianchi F, Sarcina G, Cremonesi G, Nicolosi GL, Geraci E, on behalf of the Delapril Remodelling After Acute Myocardial Infarction (DRAMI) Collaborative Group
Beneficial effects of ACE inhibitor and nitrate association on left ventricular remodelling in patients with large acute myocardial infarction. The DRAMI trial
Am Heart J 2003. 146 : 1 - 8


Carson P, Tognoni G, Cohn JN
Effect of valsartan on hospitalization: results from Val-HeFT
J Cardiac Failure 2003. 9 : 164 - 171


Maggioni AP, Franzosi MG, Latini R
Beta-adrenoceptor antagonists and antianginal drugs.
In: 2002. 25 : 227 - 235


Wong M, Staszewsky L, Volpi A, Latini R, Barlera S, Höglund C
Quality assessment and quality control of echocardiographic performance in a large multi-center international study: Valsartan in Heart Failure Trial (Val-HeFT)
J Am Soc Echocardiogr 2002. 15 : 293 - 307


Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi G, Tognoni G, Tucci C, Valagussa F, on behalf of GISSI-Prevenzione investigators
Early protection against sudden coronary death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione
Circulation 2002. 105 : 1897 - 1903


Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang Y, Bevilacqua M, Salio M, Cardano P, Dunselman PHJM, Holwerda NJ, Tognoni G, Cohn JN, for the Val-HeFT Investigators
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Val-HeFT trial
Circulation 2002. 106 : 2454 - 2458


Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang Y, Benza RL, Gottlieb SO, Kleemann TD, Rusconi F, P.M. V, Cohn JN, for the Val-HeFT Heart Failure Trial Investigators
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT Echocardiographic Study
J Am Coll Cardiol 2002. 40(5) : 970 - 975


Budaj A, Yusuf S, Mehta SR, Fox KAA, Tognoni G, Zhao F, Chrolavicius S, Hunt D, Keltai M, Franzosi MG, for the Cure trial Investigators
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups
Circulation 2002. 106 (13) : 1622 - 1626


Volpi A, Cavalli A, Turato R, Barlera S, Santoro E, Negri E, on behalf of the GISSI-3 Investigators
Incidence and short-term prognosis of late sustained ventricular tachycardia after myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-3) Data Base
Am Heart J 2001. 142 : 87 - 92


Franzosi MG, Brunetti M, Marchioli R, Marfisi MR, Tognoni G, Valagussa F, on behalf of GISSI-Prevenzione Investigators
Cost-effectiveness analysis of n-3 polyunsatured fatty acids (PUFA) after myocardial infarction. Results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial
Pharmacoeconomics 2001. 19 : 411 - 420


Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, Santoro L, Tognoni G, on behalf of the GISSI-3 Investigators
Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data
Heart 2001. 86 : 527 - 532


Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V, Malacrida R, Di Giulio P, Fumagalli R, Pelosi P, Brazzi L, Latini R, for the Prone-Supine Study Group
Effect of prone positioning on the survival of patients with acute respiratory failure
New Engl J Med 2001. 345 : 568 - 573


Collaborative Group of the Primary Prevention Project (PPP)
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice
Lancet 2001. 357 : 89 - 95


Barlera S, Chiodini DB, Franzosi MG, Tognoni G
Il PROCARDIS: un approccio attuale allo studio della genetica dell'infarto miocardico(The PROCARDIS Study: a new approach to investigate the genetics of myocardial infarction)
Ital Heart J Suppl 2001. 2 : 997 - 1004


Chiodini DB, Barlera S, Franzosi MG, Tognoni G
I geni di suscettibilità all'infarto: una revisione della letteratura(A review on the susceptibility genes of myocardial infarction)
Ital Heart J Suppl 2001. 2 : 935 - 944


Cohn JN, Tognoni G, for the Valsartan Heart Failure Investigators
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
New Engl J Med 2001. 345 : 1667 - 1675


The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation
New Engl J Med 2001. 345 : 494 - 502


Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KAA, for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
Lancet 2001. 358 : 527 - 533


Latini R, Tognoni G, Maggioni AP, Baigent C, Braunwald E, Chen ZM, Collins R, Flather M, Franzosi MG, Kjekshus J, Køber L, Liu L, Peto R, Pfeffer M, Pizzetti F, Santoro E, Sleight P, Swedberg K, Tavazzi L, Wang W, Yusuf S, on behalf of the Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group
Clinical effects of early Angiotensin-Converting Enzyme Inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. Systematic overview of individual data from 96,712 randomized patients
J Am Coll Cardiol 2000. 35 : 1801 - 1807


Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, Maggioni AP, Moccetti T, Metra M, Dei Cas L, Ghezzi P, Sipe JD, Re G, Olivetti G, Mantovani A, Latini R
PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans
Circulation 2000. 102 : 636 - 641


Maggioni AP, Latini R
Beyond hypertension: what does valsartan do for chronic heart failure and acute myocardial infarction?
J Hypertension 2000. 18 (Suppl 2) : S00


CURE Study Investigators
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease
Eur Heart J 2000. 21 : 2033 - 2041


Théroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS, Tognoni G, White HD, Willerson JR, Jessel A, for the GUARd During Ischemia Against Necrosis (GUARDIAN) Investigators
Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situation. Main results of the GUARDIAN trial
Circulation 2000. 102 : 3032 - 3038


Tognoni G
I risultati dello studio Val-HeFT
Ann Ital Med Int 2000. 15 : 160S


Santoro E, Nicolis E, Franzosi MG
Telecommunication technology for the management of large scale clinical trials: the GISSI experience
Comput Methods Programs Biomed 1999. 60 : 215 - 223


Villella M, Villella A, Barlera S, Franzosi MG, Maggioni AP, on behalf of the GISSI-2 Investigators
Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents
Am Heart J 1999. 137 : 443 - 452


Santoro E, Nicolis E, Franzosi MG, Tognoni G
Internet for clinical trials: past, present, and future
Controlled Clin Trials 1999. 20 : 194 - 201


Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E, Mauri F, for the DICE (Dobutamina nell'Insufficienza Cardiaca Estema) Investigators
Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial
Am Heart J 1999. 138 : 247 - 253


Zuanetti G, Hernández-Bernal F, Rossi A, Comerio G, Paolucci G, Maggioni AP
Relevance of heart rate as a prognostic factor in myocardial infarction: the GISSI experience
Eur Heart J 1999. 1 (Suppl. H) : H52-H57


McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni AP, Young J, Pogue J, (Writing Committee)
Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Stategies for Left Ventricular Dysfunction (RESOLVD). The RESOLVD Pilot Study Investigators
Circulation 1999. 100 : 1056 - 1064


Alli C, Avanzini F, Bettelli G, Colombo F, Torri V, Tognoni G, and General practitioners of SPAA
The long-term prognostic significance of repeated blood pressure measurements in the elderly. SPAA (Studio sulla Pressione Arteriosa nell'Anziano) 10-year follow-up
Arch Intern Med 1999. 159 : 1205 - 1212


Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A
Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of Valsartan, an angiotensin-receptor bocker, on morbidity and mortality in chronic congestive heart failure
J Cardiac Failure 1999. 5 : 155 - 160


GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial
Lancet 1999. 354 (9177) : 447 - 455


Maggioni AP, Latini R
How to use ACE ihibitors, b-blockers, and newer terapies in AMI
Am Heart J 1999. 138 : S183-S187


Maggioni AP, Tavazzi G
Introducing new treatments in clinical practice: the Italian approach to b blockers in heart failure
Heart 1999. 81 : 453 - 454


Annoni G, Luvarà G, Arosio B, Gagliano N, Fiordaliso F, Santambrogio D, Jeremic G, Mircoli L, Latini R, Vergani C, Masson S
Age-dependent expression of fibrosis-related genes and collagen deposition in the rat myocardium
Mech Ageing Dev 1998. 101 : 57 - 72


Zuanetti G, Mantini L, Hernández-Bernal F, Barlera S, Di Gregorio D, Latini R, Maggioni AP
Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction: Insignts from the GISSI-2 study
Eur Heart J 1998. 19(Supl F) : F19-F26


Malacrida R, Genoni M, Maggioni AP, Spataro V, Parish S, Palmer A, Collins R, Moccetti T, for the Third International Study of Infarct Survival Collaborative Group
A comparison of the early outcome of acute myocardial infarction in women and men
New Engl J Med 1998. 338 : 8 - 14


Franzosi MG, Maggioni AP, Santoro E, Tognoni G, Cavalieri E
Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 Trial
Pharmacoeconomics 1998. 13 : 337 - 346


Maggioni AP, Tavazzi L, Fabbri G, Lucci D, Santoro E, Canonico A, Galli M, Achilli F, Tognoni G, on behalf of GISSI-Prognosis Investigators
Epidemiology of post-infarction risk stratification strategies in a country with low volume of revascularization procedures. The GISSI-Prognosis Registry
Eur Heart J 1998. 19 : 1784 - 1794


Franzosi MG, Santoro E, De Vita C, Geraci E, Lotto A, Maggioni AP, Mauri F, Rovelli F, Santoro L, Tavazzi L, Tognoni G, on behalf of GISSI Investigators
Ten-year-follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction. Results of Gruppo per lo Studio della Sopravvivenza nell'Infarto-1 Study
Circulation 1998. 98 : 2659 - 2665


Latini R, Masson S, Jeremic G, Luvarà G, Fiordaliso F, Calvillo L, Bernasconi R, Torri M, Rondelli I, Razzetti R, Bongrani S
Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in a experimental model of left ventricular dysfunction after coronary artery occlusion
J Cardiovasc Pharmacol 1998. 31 : 601 - 608


Masson S, Latini R, Bevilacqua M, Vago T, Sessa F, Torri M, Anesini A, Salio M, Pasotti E, Agnello D, Santoro L, Catania A, Ghezzi P, Moccetti T, Maggioni AP
Within-patient variability of hormone and cytokine concentrations in heart failure
Pharmacol Research 1998. 37 : 213 - 217


ACE Inhibitor Myocardial Infarction Collaborative Group
Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100000 patients in randomized trials
Circulation 1998. 97 : 2202 - 2212


Masson S, Arosio B, Luvarà G, Gagliano N, Fiordaliso F, Santambrogio D, Vergani C, Latini R, Annoni G
Remodelling of cardiac extracellular matrix during b-adrenergic stimulation: Upregulation of SPARC in the myocardium of adult rats
J Mol Cell Cardiol 1998. 30 : 1505 - 1514


Bobbio M, Bergerone S, Maggioni AP, Malacrida R, Franzosi MG, Barlera S, Tognoni G, on the behalf of the GISSI-3 Investigators
Administration of thrombolytic therapy to 17,944 patients with acute myocardial infarction: The GISSI-3 database
Am Heart J 1998. 135 : 443 - 448


Zuanetti G, Latini R, Maggioni AP, Franzosi MG, Santoro L, Tognoni G, for the GISSI-3 Investigators
Effect of the ACE-inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI-3 study
Circulation 1997. 96 : 4239 - 4245


Huckell V, Bernstein V, Cairns JA, Crowell R, Dagenais GR, Higginson LA, Isserow S, Laramée P, Liu P, McCans JL, Orchard RC, Prewitt R, Quinn BP, Samson M, Turazza F, Warnica JW, Wielgosz A
Angiotensin-converting enzyme inhibition in myocardial infarction. Preface, Part I: Clinical Data, Parte 2: Clinical issues and contoversies
Can J Cardiol 1997. 13 : 160 - 182


Collaborative Organization for RheothRx Evaluation (CORE)
Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction
Circulation 1997. 96 : 192 - 201


Moccetti T, Malacrida R, Pasotti E, Sessa F, Genoni M, Barlera S, Turazza F, Maggioni AP, for the Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2)
Epidemiologic variables and outcome of 1972 young patients with acute myocardial infarction. Data from the GISSI-2 database
Arch Intern Med 1997. 157 : 865 - 869


Gattinoni L, Tognoni G, Brazzi L, Latini R, on behalf of the Prone-Supine Study Collaborative Group
Ventilation in the prone position
Lancet 1997. 350 : 815


The i.c.a.i.Group (gruppo di studio dell'ischemia cronica critica degli arti inferiori)
Long-term mortality and its predictors in patients with critical leg ischaemia
Eur J Vasc Endovasc Surg 1997. 14 : 91 - 95


Avanzini F, Zuanetti G, Latini R, Colombo F, Santoro E, Maggioni AP, Franzosi MG, Tognoni G, on behalf of the Gruppo Italiano di Studio sulla Sopravvivenza nell'Infarto Miocardico (GISSI) Investigators
Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine? GISSI experience, 1984-1993
Eur Heart J 1997. 18 : 1447 - 1456

 

Home Page Department  Home Page Institute

Department of Cardiovascular Research
"Mario Negri" Institute for Pharmacological Research

Via Eritrea, 62 - 20157 Milano - Italy
Tel. +39-0239014482 Fax. +39-0233200049


Scientific Info:DepCardio
Technical Info:Bioinformatics Unit